Actively Recruiting
Haploidentical Stem Cell Transplant Using Peripheral Blood Stem Cells and Cyclophosphamide for Severe Aplastic Anemia, Hypoplastic MDS, and PNH
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-11-02
56
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research evaluates the safety and effectiveness of using peripheral blood hematopoietic stem cells PBSCs from a family member combined with chemotherapy to treat severe aplastic anemia SAA, myelodysplastic syndrome MDS, and paroxysmal nocturnal hemoglobinuria PNH. These serious blood disorders cause bone marrow failure, and the study focuses on patients who lack an HLA-matched donor and have not responded to conventional therapies. The trial specifically aims to assess outcomes such as survival without moderate or severe chronic graft-versus-host disease GVHD one year after transplant. Participants receive stem cells mobilized by G-CSF injections from a haploidentical related donor. Donors undergo blood and tissue tests, receive injections for 5-7 days to boost stem cells, and have blood collected via a machine that separates stem cells. Recipients undergo chemotherapy over 8 days, one radiation treatment, and then the stem cell transplant itself. This process takes place during an approximately one-month hospital stay, followed by weekly outpatient exams and blood tests for up to 6 months. During the study, recipients have various tests including blood, urine, heart, lung, scans, and bone marrow samples. They require a caregiver for several months and may plan for fertility and legal arrangements. After day 180, participants continue monitoring with their doctor and the study team for up to 5 years to track long-term outcomes including survival, GVHD, and quality of life. The trial also measures treatment-related mortality and transplant complications.
CONDITIONS
Brief Title
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Research Team
J
Jennifer A Farren
R
Richard W Childs, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here